Aims Polypharmacy is prevalent among non-valvular atrial fibrillation (NVAF) patients and
presents a potential issue for the effective management of NVAF. This study compared the
risk of stroke/systemic embolism (SE) and major bleeding (MB) among NVAF patients with
polypharmacy newly prescribed oral anticoagulants (OACs). Methods and results A
retrospective study of NVAF patients with polypharmacy who initiated OACs from 01 January
2013 to 30 September 2015 was conducted using US CMS Medicare and four commercial …

Introduction There are a paucity of real-world data examining effectiveness and safety of non-
vitamin K antagonist oral anticoagulants (NOACs) and warfarin in nonvalvular atrial
fibrillation (NVAF) patients with prior bleeding. Methods This retrospective analysis included
data from 5 insurance claims databases and included NVAF patients prescribed OACs with
prior bleeding. One-to-one propensity score matching was conducted between NOACs and
warfarin and between NOACs in each database. Cox proportional hazards models were …